Therapix Biosciences - Two new cannabinoid programs
Therapix is expanding its cannabinoid-based clinical pipeline beyond neurological disorders to potentially treat obstructive sleep apnea (OSA), a...
82 Views
THX-ULD01 to focus on TBI
Therapix reported H117 results and provided a company update in which it announced that the planned development program for sublingual ultra-low...
98 Views
Tackling neurology with cannabinoids
Therapix is investigating the potential of new formulations of cannabinoids to address underserved diseases of the brain. It recently listed on...
118 Views
Cannabinoids for underserved diseases
Therapix recently underwent an IPO on NASDAQ in the US of 2.3m ADS (worth $13.8m) to finance the clinical development of cannabinoid products. The...
115 Views
No more insights